Tyra biosciences receives ind clearance from fda to proceed with phase 2 study of tyra-300 in pediatric achondroplasia (beach301)

– tyra-300 is the first oral fgfr-3 selective inhibitor to be well-tolerated in clinical studies – – first child with achondroplasia expected to be dosed in q1 2025 – carlsbad, calif. , oct. 28, 2024 /prnewswire/ -- tyra biosciences, inc. (nasdaq: tyra), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in fibroblast growth factor receptor (fgfr) biology, announced today that the u.s. food and drug administration (fda) cleared its investigational new drug (ind) application for tyra-300 allowing the company to proceed with a phase 2 clinical trial of tyra-300 for children with achondroplasia (beach301).
TYRA Ratings Summary
TYRA Quant Ranking